Additionally, weight neutrality, a common feature of DPP-4 inhibitors, was maintained, which is clinically beneficial for patients with type 2 diabetes and cardiovascular risk, as weight gain can worsen metabolic and cardiovascular profiles [40]. Here, DPP4 is linked to type 2 diabetes mellitus.